Mount Sinai

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with relapsed or refractory diffuse large B-cell lymphoma, according to results of a phase 1b/phase 2 trial.

An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune checkpoint inhibitors.

Approximately one in three patients diagnosed with cancer in Ontario presented to an ED in the 90 days preceding their diagnosis, according to findings published in Canadian Medical Association Journal.

Allison J. Applebaum, PhD, will lead the new Center for Caregiving at Mount Sinai.

WASHINGTON — In this video, Micaela F. Bayard, MD, shares her partnership and involvement with The Lupus and Allied Diseases Association and the Women in Rheumatology Task Force.

WASHINGTON — Healio speaks with Micaela F. Bayard, MD, about AI and its integration into clinical practice for rheumatologists.

WASHINGTON — In this video, Micaela F. Bayard, MD, discusses the shift at major conferences to include patients voices and perspectives.

WASHINGTON —Micaela F. Bayard, MD, spoke with Healio about the management of steroids and how this topic was covered at ACR Convergence 2024.

WASHINGTON — In this video, Micaela F. Bayard, MD, highlights a conversation on the evolution of biosimilars from ACR Convergence 2024.

Reproductive lifespans are limited and there is no current way to reverse ovarian aging, which is why earlier egg freezing is key to better future outcomes when family planning, according to a speaker at the Mount Sinai Women’s Health Forum.